Table 2.
Patient Characteristics
| RTOG (N=151) |
SWOG (N=322) |
NCCTG (N=540) |
Total (N=1013) |
|
|---|---|---|---|---|
| Age | ||||
| Mean (SD) | 62.7 (9.23) | 65.6 (10.70) | 65.3 (10.26) | 65.0 (10.29) |
| Median | 63.0 | 67.0 | 66.0 | 66.0 |
| Sex | ||||
| Female | 54 (35.8%) | 119 (37%) | 206 (38.1%) | 379 (37.4%) |
| Male | 97 (64.2%) | 203 (63%) | 334 (61.9%) | 634 (62.6%) |
| Race | ||||
| Missing/Unknown/Other | 4 (2.6%) | 2 (0.6%) | 19 (3.5%) | 25 (2.5%) |
| Asian | 4 (2.6%) | 3 (0.9%) | 1 (0.2%) | 8 (0.8%) |
| Black | 24 (15.9%) | 46 (14.3%) | 8 (1.5%) | 78 (7.8%) |
| Hispanic | 4 (2.6%) | 6 (1.9%) | 9 (1.7%) | 19 (1.9%) |
| Native American | 0 (0%) | 0 (0%) | 5 (0.9%) | 5 (0.5%) |
| White | 115 (76.2%) | 265 (82.3%) | 498 (92.2%) | 878 (86.7%) |
| RX | ||||
| Currently Receiving Chemotherapy | 22 (14.6%) | 322 (100%) | 449 (83.1%) | 793 (78.3%) |
| Undergone Surgery | 18 (11.9%) | 0 (0%) | 0 (0%) | 18 (1.8%) |
| Currently on RT | 111 (73.5%) | 0 (0%) | 0 (0%) | 111 (11%) |
| Placebo | 0 (0%) | 0 (0%) | 91 (16.9%) | 91 (9%) |
| Follow-up Status | ||||
| Alive | 24 (15.9%) | 40 (12.4%) | 36 (6.7%) | 100 (9.9%) |
| Dead | 127 (84.1%) | 282 (87.6%) | 504 (93.3%) | 913 (90.1%) |
| Baseline Uniscale | ||||
| N | 4 | 301 | 465 | 770 |
| Mean (SD) | 32.5 (23.6) | 51.7 (35.0) | 72.6 (22.2) | 64.2 (29.8) |
| Baseline FACT-L Total Score | ||||
| N | 191 | 156 | 347 | |
| Mean (SD) | 65.3 (13.5) | 78.7 (11.8) | 71.3 (14.4) | |
| Baseline FLIC Total Score | ||||
| N | 16 | 16 | ||
| Mean (SD) | 70.5 (14.8) | 70.5 (14.8) | ||
| Baseline LCSS Score | ||||
| N | 4 | 128 | 132 | |
| Mean (SD) | 93.3 (2.4) | 68.2 (25.0) | 69.0 (25.0) | |
| Baseline SDS Average | ||||
| N | 53 | 53 | ||
| Mean (SD) | 78.4 (12.5) | 78.4 (12.5) | ||